2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1079

Treat to Target Adherence Measurement Tool Performance in Rheumatoid Arthritis
Abstract Number: 1080

Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver Satisfaction
Abstract Number: 1081

Improving Patient-Reported Outcomes Collection and Documentation for Patients with Rheumatoid Arthritis at Multilingual, Safety Net Hospital Rheumatology Clinic
Abstract Number: 1082

Responsiveness and Minimally Clinically Important Differences of Promis Measures in Rheumatoid Arthritis
Abstract Number: 1083

Rheumatoid Arthritis Patients Achieved Better Quality of Life Than Systemic Lupus Erythematosus Patients at Sustained Remission: The Impact of Disease Diagnosis on Health-Related Quality of Life Outcomes
Abstract Number: 1084

Emdhaq: (electronic multidimensional health assessment questionnaire) to Record and Document eRAPID3 (electronic routine assessment of patient index data3) and eFAST3 (electronic fibromyalgia assessment screening tool3) in Routine Rheumatology Care
Abstract Number: 1085

Application of Lupus Nephritis Quality Measures to Understand Gaps in Care for SLE
Abstract Number: 1086

Screening and Intervention of Depression in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Abstract Number: 1087

Rheumatology Clinic Smoking Cessation Protocol Markedly Increases Quit Line Referrals
Abstract Number: 1088

Staff Protocol in Rheumatology Clinics Reduces Population-Level Rate of High Blood Pressure
Abstract Number: 1089

Large Variations in Tuberculosis Testing for New Biologic Users with Rheumatoid Arthritis Among Providers in the RISE Registry
Abstract Number: 1090

A Multidisciplinary Performance Improvement Approach to Achieving Goal Serum Uric Acid Levels in Patients with Gout
Abstract Number: 1091

The Utility of Electronic Consultation in the Management of Gout at the Veterans Affairs Medical Center
Abstract Number: 1092

The Ottawa Biologics Safety and Screening Tool
Abstract Number: 1093

Effectiveness of the Outreach Model for Rheumatology Specialty Clinics to On-Reserve First Nations in Canada: System-Level and Individual Measures of Performance and Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].